SAM
CSTL icon

Silvercrest Asset Management’s Castle Biosciences CSTL Stock Holding History

Silvercrest Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.59M Buy
268,535
+63,533
+31% +$2.08M 0.05% 387
2025
Q4 		$7.97M Sell
205,002
-162,886
-44% -$5.25M 0.05% 368
2025
Q3 		$8.38M Buy
367,888
+87,929
+31% +$1.79M 0.06% 346
2025
Q2 		$5.72M Buy
279,959
+81,157
+41% +$1.5M 0.04% 411
2025
Q1 		$3.98M Sell
198,802
-1,148
-0.6% -$28.4K 0.03% 444
2024
Q4 		$5.33M Sell
199,950
-1,971
-1% -$60K 0.04% 415
2024
Q3 		$5.76M Buy
+201,921
New +$5.14M 0.04% 361

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silvercrest Asset Management's CSTL Position: Q1 2026 in Review

Silvercrest Asset Management increased its Castle Biosciences (CSTL) stake by 31% in Q1 2026, buying an estimated $2.08M and bringing the position to 268,535 shares worth $6.59M. The position accounts for 0.05% of the portfolio, ranked #387.

Silvercrest Asset Management first reported a position in CSTL in Q3 2024 and has held it in 7 quarters since. The position peaked at $8.38M in Q3 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Silvercrest Asset Management held 268,535 shares of Castle Biosciences worth $6.59M as of Q1 2026.
  • Silvercrest Asset Management bought 63,533 Castle Biosciences shares in Q1 2026, an estimated $2.08M.
  • Castle Biosciences made up 0.05% of Silvercrest Asset Management's portfolio in Q1 2026, its #387 holding.
  • Silvercrest Asset Management first reported a position in Castle Biosciences in Q3 2024 and has held it in 7 quarters since.
  • Silvercrest Asset Management's Castle Biosciences position peaked at $8.38M in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.